CTLA4 and neoplasm: We previously found that α-CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice4, contributing to the recent FDA approval of ipilimumab, a human α-CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma5, 6.